The week in pharma: action, reaction and insight – week to June 21, 2024

By Barbara Obstoj-Cardwell. Editor

Important research news last week included US liver disease biotech Mirum Pharmaceuticals reporting positive Phase IIb data on its volixibat in cholangitis. UK pharma major AstraZeneca released disappointing Phase III trial data on its breast cancer drug Truqap (capivasertib). Also, Denmark’s Zealand Pharma presented new data on its weight loss candidate petrelintide, an amylin agonist that could pitch itself against current blockbuster obesity treatments. On the regulatory front, the USA’s Sarepta Therapeutics received a welcome expanded indication from the US Food and Drug Administration (FDA) for its Duchenne muscular dystrophy drug Elevidys to cover older patient age groups.

Volixibat update offers promising VANTAGE on approval